Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Bladder Cancer

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 31 articles:
HTML format

Single Articles

    February 2020
  1. LOKESHWAR VB, Morera DS, Hasanali SL, Yates TJ, et al
    A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Bladder Cancer Patients.
    Clin Cancer Res. 2020 Feb 24. pii: 1078-0432.CCR-19-2912.
    PubMed     Abstract available

  2. KOBATAKE K, Ikeda K, Nakata Y, Yamasaki N, et al
    Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction.
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-2230.
    PubMed     Abstract available

    November 2019
  3. KATES M, Matoso A, Choi W, Baras AS, et al
    Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials.
    Clin Cancer Res. 2019 Nov 11. pii: 1078-0432.CCR-19-1920.
    PubMed     Abstract available

    July 2019
  4. ANNELS NE, Mansfield D, Arif M, Ballesteros-Merino C, et al
    Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21.
    Clin Cancer Res. 2019 Jul 4. pii: 1078-0432.CCR-18-4022.
    PubMed     Abstract available

    April 2019
  5. BATISTA DA COSTA J, Gibb EA, Bivalacqua TJ, Liu Y, et al
    Molecular characterization of neuroendocrine-like bladder cancer.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3558.
    PubMed     Abstract available

    March 2019
  6. KISS B, van den Berg NS, Ertsey R, McKenna K, et al
    CD47-targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer.
    Clin Cancer Res. 2019 Mar 19. pii: 1078-0432.CCR-18-3267.
    PubMed     Abstract available

  7. VANTAKU V, Dong J, Ambati CR, Perera D, et al
    sMulti-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in Bladder Cancer.
    Clin Cancer Res. 2019 Mar 7. pii: 1078-0432.CCR-18-1515.
    PubMed     Abstract available

    February 2019
    DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?
    Clin Cancer Res. 2019;25:907-909.
    PubMed     Abstract available

    November 2018
  9. CHEN X, Xie R, Gu P, Huang M, et al
    Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-1656.
    PubMed     Abstract available

  10. WANG KJ, Wang C, Dai LH, Yang J, et al
    Targeting an Autocrine Regulatory Loop in Cancer Stem-Like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-0586.
    PubMed     Abstract available

    October 2018
  11. KOSHKIN VS, Garcia JA, Reynolds JP, Elson P, et al
    Transcriptomic and protein analysis of small cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1278.
    PubMed     Abstract available

    September 2018
  12. RUBIO C, Martinez-Fernandez M, Segovia C, Lodewijk I, et al
    Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status.
    Clin Cancer Res. 2018 Sep 21. pii: 1078-0432.CCR-18-0685.
    PubMed     Abstract available

  13. SEILER R, Gibb EA, Wang NQ, Oo HZ, et al
    Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1106.
    PubMed     Abstract available

    August 2018
  14. RAJA R, Kuziora M, Brohawn P, Higgs BW, et al
    Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0386.
    PubMed     Abstract available

    July 2018
  15. BIELLI P, Panzeri V, Lattanzio R, Mutascio S, et al
    The splicing factor PTBP1 promotes expression of oncogenic splice variants and predicts poor prognosis in patients with non-muscle invasive bladder cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-17-3850.
    PubMed     Abstract available

  16. LI Q, Damish A, Frazier ZJ, Liu D, et al
    ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1001.
    PubMed     Abstract available

    June 2018
  17. LELO A, Prip F, Harris BT, Solomon D, et al
    STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jun 28. pii: 1078-0432.CCR-17-3244.
    PubMed     Abstract available

    March 2018
  18. FU H, Zhu Y, Wang Y, Liu Z, et al
    Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-2687.
    PubMed     Abstract available

    January 2018
  19. VAN KESSEL KE, van der Keur KA, Dyrskjot L, Algaba F, et al
    Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups.
    Clin Cancer Res. 2018 Jan 24. pii: 1078-0432.CCR-17-2719.
    PubMed     Abstract available

    December 2017
  20. CHEN CH, Changou C, Hsieh TH, Lee YC, et al
    Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.
    Clin Cancer Res. 2017 Dec 8. pii: 1078-0432.CCR-17-2066.
    PubMed     Abstract available

    September 2017
  21. MARTINEZ VG, Rubio C, Martinez-Fernandez M, Segovia C, et al
    BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1004.2017.
    PubMed     Abstract available

  22. WU S, Zheng J, Li Y, Yu H, et al
    A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1510.2017.
    PubMed     Abstract available

    August 2017
  23. KATES M, Date A, Yoshida T, Afzal U, et al
    Preclincial Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.1082.2017.
    PubMed     Abstract available

  24. ZENG S, Zhu Y, Ma AH, Yu W, et al
    The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.0033.2017.
    PubMed     Abstract available

  25. WEN T, Yang Z, He L, Lin K, et al
    The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0882.2017.
    PubMed     Abstract available

    July 2017
  26. VANDEKERKHOVE GR, Todenhofer T, Annala M, Struss WJ, et al
    <span style="font-weight: 400;">Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer</span>.
    Clin Cancer Res. 2017 Jul 31. pii: clincanres.1140.2017.
    PubMed     Abstract available

    April 2017
  27. YANG L, Taylor J, Eustace A, Irlam J, et al
    A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High Risk Bladder Cancer Patients.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0038.2017.
    PubMed     Abstract available

    February 2017
  28. SIN ML, Mach KE, Sinha R, Wu F, et al
    Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.2610.2016.
    PubMed     Abstract available

    January 2017
  29. WANG WJ, Li CF, Chu YY, Wang YH, et al
    Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Clin Cancer Res. 2017;23:503-513.
    PubMed     Abstract available

    November 2016
  30. INMAN BA, Longo TA, Ramalingam S, Harrison MR, et al
    Atezolizumab: a PD-L1 blocking antibody for bladder cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1417.2016.
    PubMed     Abstract available

    March 2016
  31. GUIN S, Ru Y, Agarwal N, Lew CR, et al
    Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.
    Clin Cancer Res. 2016;22:1274-83.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.